Immunotherapy in myeloma: Why, when and how? by Niels W.C.J. van de Donk

Get full text

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions by Chloe O'Neill, Niels W. C. J. van deDonk

Get full text

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? by Torben Plesner, Niels W. C. J. van de Donk, Paul G. Richardson

Get full text

Loss of vision as the first manifestation of amyloid light‐chain amyloidosis by Niels W. C. J. van deDonk, Clément Huysentruyt, Mario R. P. Dhooge

Get full text

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment by Jort J. van der Schans, Niels W. C. J. van de Donk, Tuna Mutis

Get full text

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates by Christie P. M. Verkleij, Wassilis S. C. Bruins, Sonja Zweegman, Niels W. C. J. van de Donk

Get full text

Waldenström macroglobulinemia presenting as nephrotic syndrome: Renal heavy and light chain amyloidosis by Arjan J. Kwakernaak, Sophie J. Bernelot Moens, Marc L. Hilhorst, Sandrine Florquin, Niels W.C.J. van deDonk, Josephine M.I. Vos

Get full text

Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma by Marian F. Schmitz, Henny G. Otten, Laurens E. Franssen, Suzanne van Dorp, Theo Strooisma, Henk M. Lokhorst, Niels W.C.J. van de Donk

Get full text

Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma by Michelle Kinder, Nizar J. Bahlis, Fabio Malavasi, Bart de Goeij, Alexander Babich, Jocelyn Sendecki, Joshua Rusbuldt, Kevin Bellew, Colleen Kane, Niels W.C.J. van de Donk

Get full text

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS by Wassilis Bruins, Carolien Duetz, Kaz Groen, Charlotte Korst, Vera de Jonge, Christie Verkleij, Rosa Rentenaar, Meliha Cosovic, Niels W.C.J. van de Donk, Sonja Zweegman, Tuna Mutis

Get full text

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide by Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis

Get full text

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACT... by Sagar Lonial, Hang Quach, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Jesus Berdeja, Paul Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia Abad, Juliane Morando, Niels W.C.J. van de Donk

Get full text

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study by Karthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk, Katja Weisel

Get full text

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide by Mark Gurney, Arwen Stikvoort, Emma Nolan, Lucy Kirkham-McCarthy, Stanislav Khoruzhenko, Rama Shivakumar, Sonja Zweegman, Niels W.C.J. van de Donk, Tuna Mutis, Eva Szegezdi, Subhashis Sarkar, Michael O’Dwyer

Get full text

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant by Lisa C. Holthof, Arwen Stikvoort, Hilma J. van der Horst, Anne T. Gelderloos, Renée Poels, Fengzhi Li, Richard W. J. Groen, Sonja Zweegman, Niels W. C. J. van de Donk, Michael O’Dwyer, Tuna Mutis

Get full text

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJE... by Niels W.C.J. van de Donk, Alfred Garfall, Lotfi Benboubker, Katarina Uttervall, Kaz Groen, Laura Rosiñol Dachs, Caroline Hodin, Tara Stephenson, Danielle Trancucci, Alfredo Perales-Puchalt, Rachel Kobos, Arnob Banerjee, Maria-Victoria Mateos

Get full text

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study by Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani

Get full text

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma by Marina Zajec, Kristine A. Frerichs, Martijn M. van Duijn, Inger S. Nijhof, Claudia A.M. Stege, Hervé Avet-Loiseau, Theo M. Luider, Yolanda B. de Rijke, Joannes F.M. Jacobs, Niels W.C.J. van de Donk

Get full text

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma by Arwen Stikvoort, Jort van der Schans, Subhashis Sarkar, Renée Poels, Ruud Ruiter, Jyoti Naik, Huipin Yuan, Joost D. de Bruijn, Niels W. C. J. van de Donk, Sonja Zweegman, Maria Themeli, Richard Groen, Michael O’Dwyer, Tuna Mutis

Get full text

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients by Kristine A. Frerichs, Patricia W.C. Bosman, Jeroen F. van Velzen, Pieter L.A. Fraaij, Marion P.G. Koopmans, Guus F. Rimmelzwaan, Inger S. Nijhof, Andries C. Bloem, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk

Get full text